Literature DB >> 28643624

Preclinical Efficacy Testing of New Drug Candidates.

Eric L Nuermberger1.   

Abstract

This is a review of the preclinical efficacy testing of new antituberculosis drug candidates. It describes existing dynamic in vitro and in vivo models of antituberculosis chemotherapy and their utility in preclinical evaluations of promising new drugs and combination regimens, with an effort to highlight recent developments. Emphasis is given to the integration of quantitative pharmacokinetic/pharmacodynamic analyses and the impact of lesion pathology on drug efficacy. Discussion also includes in vivo models of chemotherapy of latent tuberculosis infection.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28643624     DOI: 10.1128/microbiolspec.TBTB2-0034-2017

Source DB:  PubMed          Journal:  Microbiol Spectr        ISSN: 2165-0497


  23 in total

1.  Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.

Authors:  Vikram Saini; Nicole C Ammerman; Yong Seok Chang; Rokeya Tasneen; Richard E Chaisson; Sanjay Jain; Eric Nuermberger; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Differential In Vitro Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus.

Authors:  Jin Lee; Nicole Ammerman; Anusha Agarwal; Maram Naji; Si-Yang Li; Eric Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

3.  Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges.

Authors:  S Swindells; M Siccardi; S E Barrett; D B Olsen; J A Grobler; A T Podany; E Nuermberger; P Kim; C E Barry; A Owen; D Hazuda; C Flexner
Journal:  Int J Tuberc Lung Dis       Date:  2018-02-01       Impact factor: 2.373

4.  Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.

Authors:  Paul J Converse; Deepak V Almeida; Eric L Nuermberger
Journal:  Methods Mol Biol       Date:  2022

5.  GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.

Authors:  Eric L Nuermberger; Maria Santos Martínez-Martínez; Olalla Sanz; Beatriz Urones; Jorge Esquivias; Heena Soni; Rokeya Tasneen; Sandeep Tyagi; Si-Yang Li; Paul J Converse; Helena I Boshoff; Gregory T Robertson; Gurdyal S Besra; Katherine A Abrahams; Anna M Upton; Khisimuzi Mdluli; Gary W Boyle; Sam Turner; Nader Fotouhi; Nicholas C Cammack; Juan Miguel Siles; Marta Alonso; Jaime Escribano; Joel Lelievre; Joaquin Rullas-Trincado; Esther Pérez-Herrán; Robert H Bates; Gareth Maher-Edwards; David Barros; Lluís Ballell; Elena Jiménez
Journal:  Antimicrob Agents Chemother       Date:  2022-05-24       Impact factor: 5.938

6.  Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.

Authors:  Rokeya Tasneen; Andrew Garcia; Paul J Converse; Matthew D Zimmerman; Veronique Dartois; Ekaterina Kurbatova; Andrew A Vernon; Wendy Carr; Jason E Stout; Kelly E Dooley; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2022-03-22       Impact factor: 5.938

7.  Galleria mellonella - a novel infection model for the Mycobacterium tuberculosis complex.

Authors:  Yanwen Li; John Spiropoulos; William Cooley; Jasmeet Singh Khara; Camilla A Gladstone; Masanori Asai; Janine T Bossé; Brian D Robertson; Sandra M Newton; Paul R Langford
Journal:  Virulence       Date:  2018       Impact factor: 5.882

8.  Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas.

Authors:  Kerstin Walter; Julia Kokesch-Himmelreich; Axel Treu; Franziska Waldow; Doris Hillemann; Nikolas Jakobs; Ann-Kathrin Lemm; Dominik Schwudke; Andreas Römpp; Christoph Hölscher
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

9.  Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.

Authors:  Jian Xu; Si-Yang Li; Deepak V Almeida; Rokeya Tasneen; Kala Barnes-Boyle; Paul J Converse; Anna M Upton; Khisimuzi Mdluli; Nader Fotouhi; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

10.  A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.

Authors:  Stéphane Leung-Theung-Long; Charles-Antoine Coupet; Marie Gouanvic; Doris Schmitt; Aurélie Ray; Chantal Hoffmann; Huguette Schultz; Sandeep Tyagi; Heena Soni; Paul J Converse; Lilibeth Arias; Patricia Kleinpeter; Benoît Sansas; Khisimuzi Mdluli; Cristina Vilaplana; Pere-Joan Cardona; Eric Nuermberger; Jean-Baptiste Marchand; Nathalie Silvestre; Geneviève Inchauspé
Journal:  PLoS One       Date:  2018-05-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.